北京若生智能科技有限公司
Drug Database
SI

simvastatin (simvastatin, Hanmi / simvastatin CR / Simvast CR)

✓ Approved

Hanmi Pharmaceutical · HMGCR · 小分子

什么是 simvastatin？

simvastatin 是一种小分子，由Hanmi Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名simvastatin, Hanmi, simvastatin CR, Simvast CR
公司Hanmi Pharmaceutical
药物类别小分子
分子靶点HMGCR
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Hanmi Pharmaceutical

作用机制

分子靶点

simvastatin 作用于 1 个分子靶点：

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

simvastatin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

相关研究文献

PubMedJournal of agricultural and food chemistry2026-10-23

Species-Dependent Citrus-Simvastatin Interaction Profiles in an Acute Rat Model: Integrating Drug Disposition, Hepatic Redox, and Complementary Computational Analysis.

Liao Wan-Ting WT, Chi Hsiang-Cheng HC, Li Yi-Chuan YC, Li Mei-Ling ML et al.

Citrus species differ widely in flavonoid chemistry, yet grapefruit has come to represent the genus in citrus-statin interactions. To test whether this translates into species-dependent interaction profiles, six flavonoid-profiled citrus peel extracts (Citrus limon, C. depressa Hayata, C. maxima, C. × paradisi, C. × sinensis, and C. reticulata) were compared in a standardized acute rat model spanning drug disposition, CYP3A and transporter systems, hepatic redox status, and in silico analysis. The naringin-dominated C. × paradisi produced the most coordinated disruption of CYP3A and transporter pathways, raising plasma simvastatin acid at 1 h by 506% versus the simvastatin-only group, together with the least favorable redox profile. The polymethoxyflavone-rich C. depressa Hayata perturbed disposition mildly yet raised the hepatic GSH/GSSG ratio by 227%. Hepatic active-metabolite accumulation was therefore uncoupled from redox outcome, indicating that disposition and redox response are separable axes and that grapefruit cannot represent the citrus genus.

PMID 42915885
阅读全文 →
PubMedACS nano2026-10-23

Scavenger Receptor Class B Type 1 Mediated Transport Enables Delivery Across Capillarized Liver Sinusoids in Metabolic Dysfunction-Associated Steatohepatitis.

Yuan Ruyan R, Zhang Jiamin J, Huang Yamei Y, Meng Yiyang Y et al.

Liver fibrosis in metabolic dysfunction associated steatohepatitis (MASH) lacks effective therapies, in part because therapeutic agents poorly penetrate the capillarized sinusoidal endothelium. As fibrosis progresses, liver sinusoidal endothelial cells (LSECs) become defenestrated and restrict trans-sinusoidal exchange, thereby limiting drug access to hepatic stellate cells (HSCs) within the perisinusoidal space. Here, we developed a lipoprotein mimetic liposomal nanocarrier, SV@SRB-Lip, to exploit scavenger receptor class B type 1 (SR-B1)-associated transendothelial transport across capillarized LSECs and enhance downstream delivery toward HSC-associated fibrotic regions. SV@SRB-Lip was engineered as a simvastatin loaded liposomal platform incorporating an ApoA-I-mimetic SRB peptide, an MMP-responsive linker, and a vitamin A modified lipid moiety. SV@SRB-Lip promoted transport across the LSEC monolayer in vitro, and this effect was reduced by SR-B1 silencing, supporting the involvement of SR-B1-associated endothelial transport. In MASH mice, SV@SRB-Lip enhanced hepatic delivery and distributed toward HSC associated fibrotic regions. The MMP-responsive design increased the relative accessibility of vitamin A within the fibrotic microenvironment, supporting downstream HSC associated uptake. As a result, SV@SRB-Lip increased hepatic simvastatin accumulation, suppressed HSC activation and collagen deposition, and improved MASH associated fibrosis. These findings suggest that SR-B1-associated endothelial transport can be harnessed to overcome the capillarized sinusoidal barrier and improve antifibrotic nanomedicine delivery in MASH.

PMID 42916103
阅读全文 →
PubMedNano letters2026-10-23

A DNAzyme-Driven DNA Nanotracker for Orthogonal Dual-Channel Imaging of an Oncogenic Signaling Axis and Its Pharmacological Modulation.

Zhang Qianying Q, Zheng Jingyi J, Liu Kaiyue K, Zhang Jian-Rong JR et al.

Pathway-targeted therapy has emerged as a promising strategy in cancer treatment, yet its efficacy relies on the accurate analysis of key signaling axes in living cells. The miR-140/FEN1 signaling axis, which is balanced in normal hepatocytes but dysregulated in hepatocellular carcinoma, represents a potential target for cancer therapy. Here, we present a DNAzyme-driven DNA nanotracker (DDN) for the orthogonal imaging of this pathway in dual channels with high sensitivity. The nanotracker is constructed by assembling DNAzyme-powered DNA walkers, which are responsive to miR-140 and FEN1, onto gold nanoparticles, enabling simultaneous visualization of upstream miRNA expression and downstream enzymatic activity in living cells. Leveraging this platform, we further revealed the differential pharmacological modulations of the miR-140/FEN1 signaling axis by simvastatin and myricetin. In summary, the DDN serves not only as a sensitive molecular imaging probe but also as a versatile tool for mechanistic studies, offering advanced opportunities for pathway-guided drug discovery and precision therapeutics.

PMID 42917055
阅读全文 →
PubMedRSC advances2026-10-23

LC-MS/MS-based metabolomics and PK/PD correlation analysis reveal the mechanism of hyperlipidemia treatment with Gastrodia elata fine powder.

Xie Weiwei W, Liu Meijuan M, Li Jiajun J, Zhang Yuqian Y et al.

Gastrodia elata Blume is used as both a food and a traditional medicine in East Asia. This study evaluated the lipid-lowering effects of G. elata fine powder (GFP) and the associated metabolic responses in Sprague-Dawley rats with high-fat diet (HFD)-induced hyperlipidemia. Thirty-five rats were assigned to seven groups: a normal-diet control, an untreated HFD model, three GFP groups (150, 300, or 500 mg kg-1 per administration, three times daily), and two positive-control groups receiving simvastatin or fenofibrate. Following a 6 week modeling period and a 2 week intervention, serum biochemical parameters, liver histology, and serum, urinary, and fecal metabolic profiles were assessed using biochemical assays, histological examination, and untargeted liquid chromatography-high-resolution mass spectrometry. A separate cohort of six hyperlipidemic rats received gastrodin (25 mg kg-1) for pharmacokinetic/pharmacodynamic (PK/PD) analysis. Compared with the untreated HFD group, medium- and high-dose GFP improved serum lipid profiles, reduced serum aminotransferase activities, and ameliorated hepatic histopathological changes. Metabolomic profiling revealed 14 urinary, 8 fecal, and 16 serum metabolites whose HFD-associated alterations shifted toward normal-control levels following high-dose GFP treatment. The associated pathways included phenylalanine metabolism, taurine and hypotaurine metabolism, and the tricarboxylic acid cycle. Gastrodin exhibited a biphasic plasma concentration-time profile, whereas responses of five endogenous metabolic markers lagged behind systemic drug exposure. These findings support the short-term lipid-lowering activity of GFP in HFD-fed rats and its association with changes in amino acid, bile-acid-related, and energy metabolism.

PMID 42910039
阅读全文 →
PubMedFrontiers in dental medicine2026-10-17

Comparative evaluation of the effect of simvastatin and modified triple antibiotic paste on microhardness and fracture resistance of root dentin-an in vitro study.

Kumar Pradeep P, Sreekumar Megha M, Shetty S Vidhyadhara SV, Harikrishnan Nikhil N et al.

An ideal intracanal medicament should provide effective antimicrobial action while preserving radicular dentin. This in vitro study compared the effects of simvastatin and modified triple antibiotic paste (mTAP) on root dentin microhardness and fracture resistance. Fifty-four single-rooted human premolars were randomly assigned to three groups (n = 18): simvastatin, mTAP, and control. Following root canal preparation, medicaments were placed for 1 week. Dentin microhardness was measured using a Vickers hardness tester, and fracture resistance was assessed with a universal testing machine. Statistical significance was set at p < 0.05. Both simvastatin and mTAP significantly reduced dentin microhardness compared with baseline (p < 0.001). The reduction was greatest with simvastatin (29.84 ± 3.92%), followed by mTAP (17.11 ± 7.04%) and control (8.48 ± 1.76%). Fracture resistance also differed significantly among groups (p = 0.0007), with the control group showing the highest values, followed by mTAP and simvastatin. Both medicaments were associated with changes in mechanical properties of root dentin. Simvastatin showed the greatest reduction in microhardness and the lowest fracture resistance among the tested groups. These findings should be interpreted within the limitations of the in vitro experimental model.

PMID 42890608
阅读全文 →
PubMedFrontiers in pharmacology2026-10-17

Risk of hyperglycemia with different statins by type and dose: a network meta-analysis and real-world pharmacovigilance study.

Xue Qingxia Q, Wang Feixian F, Zhang Yanyun Y, Chen Lu L

The potential diabetogenic effects of statins remain controversial, particularly with respect to differences across statin types and doses. We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) to assess the comparative effects of different statins and doses on hyperglycemia-related outcomes. The NMA was performed within a Bayesian framework. PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to April 2025. Data extraction and verification were independently conducted by two investigators. Outcomes included risk of new-onset diabetes mellitus (NODM), fasting plasma glucose (FPG), 2-h postprandial plasma glucose, and glycated hemoglobin (HbA1c). Separately, we conducted a real-world pharmacovigilance analysis using disproportionality methods based on the FDA Adverse Event Reporting System (FAERS) to identify potential hyperglycemia-related safety signals in patients without diabetes. A total of 22 RCTs, which enrolled 99,311 patients, were included. The NMA found no statistically significant differences in NODM risk among statins or compared with placebo. However, pravastatin 40 mg/day showed a numerically lower risk estimate (OR: 0.86; 95% CrI: 0.50-1.50), whereas rosuvastatin 20 mg/day and atorvastatin 80 mg/day showed relatively higher estimates. Analyses of intermediate glycemic markers, including FPG and HbA1c, revealed no significant differences across all statin regimens and placebo. In parallel, FAERS pharmacovigilance analyses identified disproportionate reporting signals for hyperglycemic events with atorvastatin (ROR: 6.11; 95% CI: 5.94-6.29), rosuvastatin (ROR: 2.44; 95% CI: 2.31-2.58), and simvastatin (ROR: 1.22; 95% CI: 1.13-1.32). No statistically significant differences in glycemic outcomes were observed among individual statins or compared with placebo. However, numerical variations in point estimates across randomized evidence and pharmacovigilance signals suggest possible differences in glycemic profiles among statins. Pravastatin showed numerically lower risk estimates; however, these findings were accompanied by substantial uncertainty. Further prospective studies are needed to clarify these observations.

PMID 42890578
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多simvastatin